Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
最近の投稿
- 1
Authorities arrest 7 bodyguards in connection with a Mexican mayor's assassination - 2Can scientists detect life without knowing what it looks like? Research using machine learning offers a new way
- 3Storm Goretti sweeps United Kingdom, France with winds over 120 mph
- 4Triumph’s Gorgeous, Super-Affordable and Approachable New Street Motos Share a Heart But Not a Soul
- 5How did I get my own unique set of fingerprints?
- Netanyahu expects Iran's leadership to fall
- Evidence of lost baptismal rite stage uncovered in Byzantine era cathedral near Sea of Galilee
- Nature: 10 High priority Setting up camp Spots In Europe
- The most effective method to Redesign the Sound Framework in Your Smash 1500.
- Pfizer in $41.5 million settlement with Texas over ADHD drug for children
- 5 Cell phones of the Year
- Kids who get 2-month vaccines on time 7 times more likely to receive MMR shot: Study
- India's top court hears challenges to ruling on women's entry into temple
- Noctourism: the new safari travel trend that's changing the wildlife we can photograph in Africa
